



Minireview

The N-glycosylation pattern of *Caenorhabditis elegans*

Katharina Paschinger,* Martin Gutternigg, Dubravko Rendić and Iain B. H. Wilson

Department für Chemie, Universität für Bodenkultur, Muthgasse 18, A-1190 Wien, Austria

Received 1 October 2007; received in revised form 7 December 2007; accepted 17 December 2007

Available online 28 December 2007

Presented at Eurocarb 14th Lübeck, Germany, September 2007

Abstract—Determining the exact nature of N-glycosylation in *Caenorhabditis elegans*, a nematode worm and genetic model organism, has proved to have been an unexpected challenge in recent years; a wide range of modifications of its N-linked oligosaccharides have been proposed on the basis of structural and genomic analysis. Particularly mass spectrometric studies by a number of groups, as well as the characterisation of recombinant enzymes, have highlighted those aspects of N-glycosylation that are conserved in animals, those which are seemingly unique to this species and those which are shared with parasitic nematodes. These data, of importance for therapeutic developments, are reviewed.

© 2007 Elsevier Ltd. All rights reserved.

Keywords: *Caenorhabditis*; Biosynthesis; Fucose; N-Glycans; Mass spectrometry

Contents

1. Introduction	2041
2. A summary of the N-glycomic data	2042
3. Unexpected modifications in the light of the glycogenomic potential.	2045
4. Use of mutants in worm glycomics	2046
5. Conclusion	2048
Acknowledgements.	2048
References.	2048

1. Introduction

Although *Caenorhabditis elegans* was the first multicellular organism to have its genome sequenced, it is only in the past few years that information regarding its glycome has been accumulated. Despite the simple

anatomy of *C. elegans*, the complexity of the glycans existing in the worm is striking—especially when compared to the glycan pattern present in the fruitfly *Drosophila melanogaster*, another model organism. Since the structural variation is so high, a potential classification of the worm's N-glycans into several classes has been proposed. Thereby, oligomannosidic, paucimannosidic, truncated complex, phosphorylcholine (PC)-containing and fucose-rich N-glycans were defined (see Fig. 1).¹ Furthermore, the O-glycans and glycolipids of *C. elegans* also show structural peculiarities, with 'pseudo-core 2' O-glycans of the form Galβ1,3(Glcβ1,6)-GalNAc, some modified with fucose, and *arthro*-series glycosphingolipids with a GalNAcβ1,4GlcNAcβ1,

Abbreviations: CCM, core chitobiose modification; GnGn, MM, etc., biantennary N-glycans with either terminal GlcNAc or Man residues for symbolic structures see Figure. 4; GnT, N-acetylglucosaminyltransferase (GlcNAc-T); LacdiNAc, GalNAcβ1,4GlcNAcβ-R; Lewis x, Galβ1,4(Fucα1,3)GlcNAcβ-R; *fut*-, fucosyltransferase gene or mutant; FUT-, fucosyltransferase protein; PC, phosphorylcholine

* Corresponding author. Tel.: +43 1 36006 6541; fax: +43 1 36006 6076; e-mail: katharina.paschinger@boku.ac.at




Figure 1. Putative N-glycan structures reported as being present in the worm. The symbols used are blue squares for GlcNAc, green circles for Man, yellow circles for Gal, open circles for undefined hexose residues and red triangles for Fuc residues (nomenclature of the Consortium for Functional Glycomics). The figure is based on that of Haslam and Dell,¹ with the exception of the depiction of the core chitobiose modifications (CCMs) with up to probably three Gal β 1,4Fuc disaccharides.¹⁰ Potential methylations of, for example, fucose are not shown.

3Man β 1,4Glc-Cer core, some containing also fucose and phosphorylcholine.²⁻⁴

As a harmless member of a family of organisms (nematodes), which are often causing parasitic diseases in plants, farm animals and man, *C. elegans* is a potent model for studying the genetic basis for glycomic variation in its relatives. In this context, particularly the PC-containing glycans of nematodes have attracted attention due to their immune-modulating function;⁵ just as the Tarnhelm made Siegfried invisible in the Nibelungen legend, phosphorylcholine may make nematodes immunologically ‘camouflaged’.

2. A summary of the N-glycomic data

In total, six laboratories have been involved in the analysis of *C. elegans* glycans with mostly overlapping results.⁶⁻¹¹ An analysis of all published data (summarised in Table 1) demonstrates that *C. elegans* has an extraordinarily diverse N-glycosylation repertoire. Considering only the *m/z* values obtained, it appears

that nearly 150 structures are present in wild-type (N2) and/or mutant worms (see Table 1^{3,6,12-14}).

Since a hexose residue can either be a mannose or a galactose or, in the case of Hex10, even a glucose and that a HexNAc can either be *N*-acetylglucosamine or *N*-acetylgalactosamine, the number of structures, including structural isomers, is enormous and in obvious contrast to the aforementioned relatively simple anatomy or the low position in the phylogenetic tree. Only a few attempts have been made to solve the actual structure of the individual glycans, which is mainly due to the low amounts of these compounds; of those examined by traditional HPLC-based techniques, in general only the most abundant, but less interesting, were subject to a more intensive analysis.^{7,15}

The most abundant class of glycans in *C. elegans*, and at the same time the most conserved amongst eukaryotes, are the high mannose type glycans (i.e., the oligomannosidic Man₅₋₉GlcNAc₂ and Glc₁Man₉GlcNAc₂; see Fig. 1); these were found by all groups no matter which method was used. Only minor amounts of truncated hybrid and complex glycans with one or two HexNAc res-

Table 1. Summary of data published on the structural variation of N-glycans of the model organism *C. elegans*

<i>m/z</i>	Additional to the core GlcNAc ₂ [M+Na] ⁺	Refs. 6,12,14	Ref. 10	Ref. 13	Refs. 8,16,17	Ref. 11	Refs. 3,9	Refs. 7,15
772	Hex2	W↓K nd X	nd	nd	nd	nd	+	nd
813	<i>HexNAc1 Hex1</i>	nd	nd	nd	16	nd	nd	nd
918	Hex2 Fuc1	W K nd X	A H↓	nd	nd	nd	+	nd
932	Hex2 Fuc1Me	W K nd nd	nd	nd	nd	nd	nd	nd
934	Hex3	W K M↓X	A H	W nd	8,16,17	ConA	+	MM
948	Hex3 Me1	nd	nd	nd	8	nd	nd	nd
975	<i>HexNAc1 Hex2</i>	nd	nd	nd	16	nd	nd	nd
1064	Hex2 Fuc2	W K nd X	nd H	W nd	nd	nd	+	MOF ³ F ⁶
1078	Hex2 Fuc2Me	W K nd nd	nd H	nd	nd	L	nd	nd
1080	Hex3 Fuc1	W K nd X	A H	W nd	8,16,17	ConA, L	+	MMF ⁶
1094	Hex3 Fuc1Me	W K nd nd	nd	nd	8	nd	nd	nd
1096	Hex4	W K M X↓	A H	W G	8,16,17	ConA, L	+	nd
1110	Hex4 Me1	nd	nd	nd	8	nd	nd	nd
1137	<i>HexNAc1 Hex3</i>	W K nd X	A H	W nd	8,16,17	ConA, L	+	MGn,GnM
1178	<i>HexNAc2 Hex2</i>	nd	nd	nd	8	nd	nd	nd
1226	Hex3 Fuc2	W K nd X	A↓H	W nd	nd	ConA, L	+	MMF ³ F ⁶
1229	<i>Hex2 Fuc2 PC1</i>	nd	nd	nd	8	nd	nd	nd
1240	Hex3 Fuc2Me	W K M X	A↓H	W nd	nd	L	nd	nd
1242	Hex4 Fuc1	W K M↓X↓	A H	W G↓	8,16,17	ConA, L	+	nd
1244	<i>Hex3 Fuc1 PC1</i>	nd	nd	nd	8	nd	nd	nd
1256	Hex4 Fuc1Me	W K M nd	A↓H	W nd	8	L	nd	nd
1258	Hex5	W K M X	A H	W G	8,16,17	ConA, L	+	Man5
1270	Hex4 Fuc1Me2	nd K nd nd	nd	nd	8	nd	nd	nd
1283	<i>HexNAc1 Hex3Fuc1</i>	W K nd X	A↓H	nd	8,16	ConA, L	+	nd
1299	<i>HexNAc1 Hex4</i>	nd	nd	nd	16	ConA	nd	nd
1302	<i>HexNAc1 Hex3 PC1</i>	W K nd X	+	nd	8	nd	+	nd
1340	<i>HexNAc2 Hex3</i>	W K nd X	A↓H↓	W↓nd	8,16,17	L	+	GnGn
1372	Hex3 Fuc3	W nd nd nd	A↓H↓	W nd	nd	L	+	nd
1386	Hex3 Fuc3Me	W K nd nd	A↓H	W nd	nd	nd	nd	nd
1388	Hex4 Fuc2	W K nd nd	A↓H	W nd	17	ConA, L	+	nd
1401	Hex4 Fuc2Me	W K M↓X↓	A↓H	W nd	8	L	+	nd
1403	Hex5 Fuc1	W K M X↓	A↓H	W G↓	8,16,17	ConA, L	+	nd
1415	Hex4 Fuc2Me2	nd K nd nd	nd H↓	nd	nd	nd	nd	nd
1418	Hex5 Fuc1Me	W↓K M X↓	A↓H↓	W↓nd	8	nd	nd	nd
1420	Hex6	W K M X	A H	W G	8,16,17	ConA	+	Man6
1429	<i>HexNAc1 Hex3Fuc2</i>	nd nd nd X	nd	nd	nd	nd	nd	nd
1432	Hex5 Fuc1Me2	nd K M↓nd	nd	nd	nd	nd	nd	nd
1434	Hex6 Me	nd nd M↓nd	nd	nd	nd	nd	nd	nd
1445	<i>HexNAc1 Hex4Fuc1</i>	W↓nd nd X	nd	nd	16	nd	nd	nd
1448	<i>HexNAc1 Hex3Fuc1 PC1</i>	W↓K nd nd	+	nd	nd	nd	+	nd
1459	<i>HexNAc1 Hex4Fuc1Me1</i>	nd nd M X	nd	nd	nd	nd	nd	nd
1461	<i>HexNAc1 Hex5</i>	nd nd M nd	nd	nd	8,16	ConA	nd	nd
1464	<i>HexNAc1 Hex4 PC1</i>	nd	nd	nd	8	nd	nd	nd
1486	<i>HexNAc2 Hex3Fuc1</i>	W K nd X	A↓H↓	nd	nd	nd	+	nd
1502	<i>HexNAc2 Hex4</i>	nd	nd	nd	8,16,17 A	nd	nd	nd
1505	<i>HexNAc2 Hex3 PC1</i>	W↓K nd X	+	nd	8	nd	+	nd
1534	Hex4 Fuc3	W nd nd nd	A↓H	W nd	nd	ConA, L	+	nd
1543	<i>HexNAc3 Hex3</i>	nd	nd	nd	8,17	nd	+	nd
1547	Hex4 Fuc3Me	W K nd nd	A H	W nd	nd	L	+	nd
1550	Hex5 Fuc2	W K nd nd	A H	W G↓	16,17	ConA, L	+	nd
1555	<i>HexNAc3 Hex2Fuc1 Me2</i>	nd	nd	nd	8	nd	nd	nd
1561	Hex4 Fuc3Me2	nd K nd nd	A↓H↓	nd	nd	nd	+	nd
1564	Hex5 Fuc2Me	W↓K M X↓	A↓H↓	W nd	8	L	+	nd
1566	Hex6 Fuc1	nd nd M nd	nd	nd G	8	L	+	nd
1572	<i>Hex4Fuc1 PC2</i>	nd	nd	nd	8	nd	nd	nd
1578	Hex5 Fuc2Me2	nd K M↓nd	nd	nd	nd	nd	nd	nd
1580	Hex6 Fuc1Me	nd nd M nd	nd	nd	nd	L	nd	nd
1582	Hex7	W K M X	A H	W G	8,16,17	ConA	+	Man7
1591	<i>HexNAc1 Hex4Fuc2</i>	nd nd nd X	nd	nd	nd	nd	nd	nd
1594	Hex6 Fuc1Me2	nd K nd nd	nd	nd	nd	nd	nd	nd
1605	<i>HexNAc1 Hex4Fuc2 Me</i>	nd nd M nd	nd	nd	nd	nd	nd	nd
1607	<i>HexNAc1 Hex5Fuc1</i>	nd nd M nd	nd	nd	nd	nd	nd	nd
1620	<i>HexNAc1 Hex5Fuc1 Me</i>	nd nd M nd	nd	nd	nd	nd	nd	nd

(continued on next page)

Table 1 (continued)

<i>m/z</i>	Additional to the core GlcNAc ₂ [M+Na] ⁺	Refs. 6,12,14	Ref. 10	Ref. 13	Refs. 8,16,17	Ref. 11	Refs. 3,9	Refs. 7,15
1623	<i>HexNAc1 Hex6</i>	nd nd M nd	nd	nd	8	nd	nd	nd
1626	<i>HexNAc1 Hex5PC1</i>	nd nd M nd	nd	nd	nd	nd	nd	nd
1629	<i>HexNAc1 Hex4 PC2</i>	nd	nd	nd	8	nd	nd	nd
1635	<i>HexNAc1 Hex5Fuc1 Me2</i>	nd nd M↓nd	nd	nd	nd	nd	nd	nd
1637	<i>HexNAc1 Hex6 Me</i>	nd nd M nd	nd	nd	nd	nd	nd	nd
1647	<i>HexNAc2 Hex4Fuc1</i>	nd	nd	nd	8	nd	nd	nd
1650	<i>HexNAc2 Hex3Fuc1 PC1</i>	nd nd nd X↓	+	nd	nd	nd	+	nd
1670	<i>HexNAc2 Hex3 PC2</i>	nd nd nd X↓	nd	nd	8	nd	nd	nd
1680	<i>Hex4 Fuc4</i>	W↓nd nd nd	A↓H	W nd	nd	nd	+	nd
1689	<i>HexNAc3 Hex3Fuc1</i>	nd	nd	nd	nd	nd	+	nd
1694	<i>Hex4 Fuc4Me</i>	W nd nd nd	A↓H	W nd	nd	L	nd	nd
1696	<i>Hex5 Fuc3</i>	W nd nd nd	A H	W nd	nd	ConA, L	+	nd
1704	<i>HexNAc3 Hex4</i>	nd	nd	nd	17 A	nd	nd	nd
1708	<i>HexNAc3 Hex3 PC1</i>	nd	+	nd	8	nd	+	nd
1710	<i>Hex5 Fuc3Me</i>	W K nd X	A↓H	W nd	nd	L	nd	nd
1712	<i>Hex6 Fuc2</i>	W↓K nd nd	A↓H	W G↓	nd	L	+	nd
1724	<i>Hex5 Fuc3Me2</i>	nd K nd nd	nd H↓	nd	nd	nd	nd	nd
1725	<i>Hex6 Fuc2Me</i>	nd K M nd	nd H↓	nd	nd	L	nd	nd
1728	<i>Hex7 Fuc1</i>	nd nd M↓nd	nd	nd G	nd	nd	nd	nd
1742	<i>Hex7 Fuc1Me</i>	nd nd M nd	nd	nd	nd	nd	nd	nd
1744	Hex8	W K M X	A H	W G	8,16,17	ConA	+	Man8
1745	<i>HexNAc4 Hex3</i>	nd	nd	nd	16	nd	+	Tetra-ant.
1753	<i>HexNAc1 Hex5Fuc2</i>	nd	nd	nd	17 A	nd	nd	nd
1753	<i>Hex5 PC3</i>	nd	nd	nd	16	nd	nd	nd
1769	<i>HexNAc1 Hex6Fuc1</i>	nd nd M nd	nd	nd	nd	nd	nd	nd
1772	<i>HexNAc1 Hex5Fuc1 PC1</i>	nd nd M nd	nd	nd	nd	nd	nd	nd
1781	<i>HexNAc1 Hex5Fuc2 Me2</i>	nd nd M↓nd	nd	nd	nd	nd	nd	nd
1783	<i>HexNAc1 Hex6Fuc1 Me</i>	nd nd M nd	nd	nd	nd	nd	nd	nd
1797	<i>HexNAc1 Hex6Fuc1 Me2</i>	nd nd M↓nd	nd	nd	nd	nd	nd	nd
1816	<i>HexNAc2 Hex3Fuc1 PC2</i>	nd nd nd X↓	nd	nd	nd	nd	nd	nd
1832	<i>HexNAc2 Hex4 PC2</i>	nd	nd	nd	8	nd	nd	nd
1842	<i>Hex5 Fuc4</i>	W↓nd nd nd	A↓H	W nd	17 A	nd	+	nd
1851	<i>HexNAc3 Hex4Fuc1</i>	nd	nd	nd	8	nd	nd	nd
1854	<i>HexNAc3 Hex3Fuc1 PC1</i>	nd	+	nd	8	nd	+	nd
1855	<i>Hex5 Fuc4Me</i>	W nd nd X	A H	W nd	nd	L	+	nd
1857	<i>Hex6 Fuc3</i>	W↓nd nd X↓	A↓H	W nd	nd	ConA, L	+	nd
1866	<i>HexNAc3 Hex5</i>	nd	nd	nd	8,16,17 A	nd	nd	nd
1869	<i>Hex5 Fuc4Me2</i>	nd	nd H↓	nd	nd	L	nd	nd
1872	<i>Hex6 Fuc3Me</i>	W↓K nd X↓	A↓H	W nd	nd	L	nd	nd
1873	<i>HexNAc3 Hex3 PC2</i>	nd	nd	nd	8	nd	nd	nd
1874	<i>Hex7 Fuc2</i>	W↓nd nd X↓	nd	W↓G↓	nd	nd	nd	nd
1888	<i>Hex7 Fuc2Me</i>	nd nd M↓nd	nd	nd	nd	nd	nd	nd
1890	<i>Hex8 Fuc1</i>	nd	nd	nd G↓	nd	nd	nd	nd
1904	<i>Hex8 Fuc1Me</i>	W↓K M nd	nd	nd	nd	nd	nd	nd
1906	Hex9	W K M X	A H	W G	8,16,17	ConA	+	Man9
1924	<i>HexNAc2 Hex3Fuc4</i>	nd	nd	nd	8	nd	nd	nd
1929	<i>HexNAc1 Hex6Fuc2 Me</i>	nd nd M nd	nd	nd	nd	nd	nd	nd
1931	<i>HexNAc1 Hex7Fuc1</i>	nd nd M↓nd	nd	nd	nd	nd	nd	nd
1948	<i>HexNAc5 Hex3</i>	nd	nd	nd	nd	nd	+	nd
1975	<i>HexNAc2 Hex5Fuc1 PC1</i>	nd	nd	nd	8	nd	nd	nd
1997	<i>HexNAc3 Hex4Fuc2</i>	nd	nd	nd	8	nd	nd	nd
2000	<i>HexNAc3 Hex3Fuc2 PC1</i>	nd	nd	nd	8	nd	nd	nd
2004	<i>Hex6 Fuc4</i>	nd	nd H↓	W nd	nd	nd	nd	nd
2016	<i>HexNAc3 Hex4Fuc1 PC1</i>	nd	nd	nd	8	nd	nd	nd
2018	<i>Hex6 Fuc4Me</i>	W↓nd nd X↓	A↓H	W nd	nd	L	nd	nd
2020	<i>Hex7 Fuc3</i>	nd	nd H	W nd	nd	L	nd	nd
2032	<i>Hex6 Fuc4Me2</i>	nd	nd H↓	nd	nd	nd	nd	nd
2034	<i>Hex7 Fuc3Me</i>	nd	nd H↓	W↓nd	nd	nd	nd	nd
2036	<i>Hex8 Fuc2</i>	nd	nd	nd G↓	nd	nd	nd	nd
2051	<i>Hex9 Fuc1</i>	nd	nd	nd G↓	nd	nd	nd	nd
2069	Hex10	W↓K M↓X↓	A↓H↓	W↓G↓	8,16	nd	+	GlcMan9
2076	<i>HexNAc4 Hex3 PC2</i>	nd	nd	nd	8	nd	nd	nd
2089	<i>HexNAc1 Hex6Fuc3 Me2</i>	nd nd M↓nd	nd	nd	nd	nd	nd	nd
2091	<i>HexNAc1 Hex7Fuc2 Me</i>	nd nd M↓nd	nd	nd	nd	nd	nd	nd

Table 1 (continued)

<i>m/z</i>	Additional to the core GlcNAc ₂ [M+Na] ⁺	Refs. 6,12,14	Ref. 10	Ref. 13	Refs. 8,16,17	Ref. 11	Refs. 3,9	Refs. 7,15
2159	<i>HexNAc3 Hex5Fuc2</i>	nd	nd	nd	8	nd	nd	nd
2162	<i>HexNAc3 Hex4Fuc2 PC1</i>	nd	nd	nd	8	nd	nd	nd
2166	Hex7 Fuc4	nd	nd H↓	W↓nd	nd	nd	nd	nd
2180	Hex7 Fuc4Me	nd	nd H↓	W↓nd	nd	nd	nd	nd
2182	Hex8 Fuc3	nd	nd H↓	W↓nd	nd	nd	nd	nd
2200	<i>HexNAc4 Hex4Fuc2</i>	nd	nd	nd	8	nd	nd	nd
2219	<i>HexNAc4 Hex4Fuc1 PC1</i>	nd	nd	nd	8	nd	nd	nd
2346	<i>HexNAc4 Hex4Fuc3</i>	nd	nd	nd	8	nd	nd	nd
2365	<i>HexNAc4 Hex4Fuc2 PC1</i>	nd	nd	nd	8	nd	nd	nd
2384	<i>HexNAc4 Hex4Fuc1 PC2</i>	nd	nd	nd	8	nd	nd	nd
2403	<i>HexNAc5 Hex4Fuc2</i>	nd	nd	nd	8	nd	nd	nd
2479	<i>HexNAc6 Hex4 PC1</i>	nd	nd	nd	8	nd	nd	nd
2527	<i>HexNAc4 Hex5Fuc2 PC1</i>	nd	nd	nd	8	nd	nd	nd
2530	<i>HexNAc4 Hex4Fuc2 PC2</i>	nd	nd	nd	8	nd	nd	nd

To summarise the glycosylation potential, data published in the literature so far on *C. elegans* from various laboratories, generally based on mass spectrometry of the wild-type N2 strain, are combined into this table. In general mixed-stages of wild-type or deletion/knock out mutants of *C. elegans* were used except in one study analysing the glycan profile of developmental stages.⁸

Notes: **Hex** for hexose (mannose, glucose and galactose), **HexNAc** either *N*-acetylglucosamine or *N*-acetylgalactosamine, **Fuc** for fucose, **PC** for phosphorylcholine, **Me** for methyl group; To simplify the table, the inner two GlcNAc residues are not included in the structural formulae. High mannosidic N-glycans are highlighted in bold, complex and hybrid types with PC and/or additional HexNAc residues are in italics. The glycome of the wild-type N2 worm (**W**) is compared, for the Refs. 6, 12 and 14, to the glycomes of various mutants (**K** for *Ce fut-1* deletion mutant (VC 378), **M** for the mannosidase II mutant (*aman-2*, tm1078), **X** for the hexosaminidase mutant (*hex-2*, tm2350)) and, for Ref. 13, to the triple GnTI knock-out mutant (**G**). A structure annotated with [W nd] is, therefore, found in the wild-type but not detected (**nd**) in the mutant. Ref. 10 compared the occurrence of certain structures when either hydrazine (**H**) or PNGase A (**A**) was used to release the glycans. In this case, [nd H↓] means that the structure was observed after release with hydrazine but not with PNGase A; a relative abundance of ≤5% is marked with an ↓. Refs. 8,16 and 17 generally used PNGase F to release the glycans, only a few more structures were found when using PNGase A (**A**) instead. Ref. 11 analysed the N-glycans of soluble glycoproteins separated through their binding to the lectin ConA (**ConA**) or to galectin (**L**). In this case, [L] means that the structure was found on galectin-bound glycoproteins. For Refs. 3,9 and 10 a + marks a detected structure. Refer to Figure 4 for the glycan abbreviations used for Refs. 7 and 15.

idues on the core pentasaccharide were found by all, while multiple non-reducing terminal 6-phosphorylcholine-substituted GlcNAc residues ('PC-rich' glycans) were only observed in some studies (see also Fig. 1). Highly-fucosylated truncated structures and methyl groups closely associated to the fucosylated structures were sometimes overlooked although they represent an important subset of the features present on *C. elegans* glycans.

The observed differences in the results are partly dependent on the method used to release the glycans or are due to the overall sensitivity of the analysis method itself. In the cases where the analysis is more or less exclusively based on mass spectrometric methods, careful interpretation is the key especially when being confronted with unusual and partially unknown structures such as the special 'core chitobiose modifications' (CCMs; see also Fig. 1).¹⁰

3. Unexpected modifications in the light of the glycogenomic potential

The core modifications found by Reinhold's group included a galactose residue linked β1,4 to the core α1,6-fucose with another hexose present on the galactose and another Galβ1,4Fuc disaccharide present on the 3-hydroxyl group of the protein linked GlcNAc.¹⁰ A third Hex-Fuc modification, attached via the 3-hydroxyl of

the second core GlcNAc, was not further analysed due to the low amount. The relevant 4-substituted fucose observed in the CCMs was neither found nor perhaps looked for, by GC-MS, in either *C. elegans*¹⁸ or in any other closely-related nematodes like *Dictyocaulus viviparus*,¹⁹ *Haemonchus contortus*²⁰ and *Parelaphostrongylus tenuis* that were examined.²¹ Such a Hex-Fuc motif was previously found only in octopus rhodopsin²² and key-hole limpet haemocyanin.²³ On the other hand, the presence of these core modifications could be an explanation for the multiply fucosylated paucimannosidic structures found by nearly all groups studying *C. elegans* glycans. In a recent analysis, galactose-substituted core α1,6-fucose was found to be a rather prominent modification of the N-glycans of a hexosaminidase (*hex-2*) mutant.¹²

Other than 1,4-substituted fucose, terminal GalNAc was not found in *C. elegans* by GC-MS, although in our studies a functional recombinant *C. elegans* GalNAc transferase (encoded by the *bre-4*/Y73E7A.7 gene), a member of the glycosyltransferase family 7, was able to add two GalNAcs to an asialoagalactoglycopeptide (the so-called GnGn) forming two LacdiNAc motifs in vitro. Furthermore, the same functional enzyme also transferred GalNAc to O-glycan-like substrates in vitro²⁴ and is presumed to be also involved in glycolipid biosynthesis in the worm in vivo (indeed, the name *bre-4* refers to *Bacillus* toxin resistance; one of these *Bacillus* toxins uses worm glycolipids as receptors).

When BRE-4 (the name in capitals refers to the protein, rather than the gene) was expressed in CHO cells, the enzyme was also able to participate in the synthesis of poly LacdiNAc motifs.²⁵

Nevertheless, the *anti*-LacdiNAc antibody 100 2H5-A raised against *Schistosoma* glycans²⁶ showed a relatively weak binding to a wild-type N2 *C. elegans* extract (unpublished data), which might reflect the absence of LacdiNAc units in the worm, which are usually present in *Schistosoma* glycans.^{27,28} The apparent lack of GalNAc residues on *C. elegans* N-glycans might be due to a restricted supply of the nucleotide sugar and may be influenced by the metabolism of the worms when growing in, for example, liquid culture. Other mouse IgM sera tested against mono-fucosylated LacdiNAc, difucosylated LacdiNAc and Lewis x did not crossreact with the *C. elegans* extracts, suggesting the absence of such modifications in this organism (unpublished data); thus it is unclear whether the BRE-4 GalNAc transferase has a role in N-glycan biosynthesis in the worm. On the other hand, in parasitic nematodes, LacdiNAc has been found on *Trichinella* N-glycans,²⁹ whereas Lewis x moieties have been found in *Dictyocaulus*.¹⁹ In its fucosylated form, LacdiNAc is present not just in schistosomes, but also on bee venom glycoproteins.³⁰

In general, glycans are a result of the interplay of glycan substrates, glycosidases and glycosyltransferases and, as such, are obviously related to the ‘glycogenomic’ potential of a species. The genome of *C. elegans*, published in 1998, can be searched for the glycosyltransferases relevant to N-glycan biosynthesis. The presence or absence of such genes can therefore be taken into consideration when proposing glycan structures.

Several glycosyltransferases like GnTIII, GnTIV and GnTVI (all three forming β 1,4-GlcNAc linkages) and α 2,3/6/8-sialyltransferases, leading to the formation of the ‘normal’ complex type N-glycans with tetra- or pentaantennary, sialylated structures in vertebrates, have no obvious homologues in the worm. The β 1,2-xylosyltransferase, responsible for the xylosylation of the N-glycan core in plants and trematodes, is absent too. Structures originating from these enzymatic activities are, therefore, very likely not present in the worm.

On the other hand, the three homologues of GnTI, one of GnTII and one of GnTV only give rise to a restricted number of complex glycans (see Fig. 2 for an explanation of their activities); the low amount of bi- and triantennary glycans can be explained by a high endogenous activity of a Golgi hexosaminidase removing exclusively the GlcNAc residue from the α 1,3-antennae, similar to that in insect cells.³¹

The high fucose content of the N-glycans is reflected by the finding of one core α 1,6-fucosyltransferase homologue (FUT-8), one characterised α 1,2- (out of twenty-five putative) and five α 1,3/4-fucosyltransferases in the genome. One of the α 1,3-fucosyltransferases (FUT-1;




Figure 2. N-Acetylglucosaminyltransferase homologues in *C. elegans*. The GnTI activities transferring to the α 1,3-antenna, encoded by the *gly-12*, *gly-13* and *gly-14* genes, are counteracted by the Golgi hexosaminidase(s). The activities of the GnTII and GnTV homologues (encoded, respectively, by the *gly-20* and *gly-2* genes) are presumed to be dependent on the prior action of GnTI. For GnTIII and GnTIV no obvious homologues have been found.

also known as CEFT1) was proven to modify the N-glycan core, but is inhibited in the presence of the GlcNAc residue transferred by GnTI.⁶ Of the remaining four α 1,3-fucosyltransferases, two were found to produce Lewis x structures using Gal β 1,4GlcNAc-pNP as a substrate, whereas a third one was using a LacdiNAc structure as its acceptor; however, FUT-4 (otherwise known as CEFT5) was not active with any tested substrate.³² The presence of enzymes with Lewis-type activities contrasts with the aforementioned lack of any obvious expression of Lewis-type epitopes; thus, the actual role of such enzymes *in vivo* still needs to be elucidated. The activity of one of the 25 homologues of α 1,2-fucosyltransferases present could be, in theory, responsible for the *in vitro* or *in vivo* synthesis of the 2-linked fucosylated glycans similar to the O-glycan or glycolipid modifications in *Schistosoma* eggs or cercarial glycolipid, which possess Fuc α 1,2/+Fuc α 1,2Fuc α 1,3 on a backbone of HexNAc-containing units (see Fig. 3).^{33–35} Certainly, up to three fucose residues, including α 1,2-linked 2-O-methylfucose,³ have been observed on O-glycans of wild-type N2 worms.

Finally, the galactosyltransferase families capable of transferring Gal or GalNAc either β 1,3 to GlcNAc, β 1,3 to GalNAc or β 1,4 to GlcNAc have about 20 members in the worm³⁶ and are, therefore, candidates for being responsible for the unusual hexose modifications of fucose-containing structures.

4. Use of mutants in worm glycomics

Since the final definition of the N-glycan structures and the relevant biosynthetic pathways in the worm is still




Figure 3. An example product of fucosyltransferases in schistosomes modifying LacdiNAc units of O-glycans; whether similar reactions occur in *C. elegans* has yet to be clarified.

One example is the triple knock out of all genes encoding forms of GnTI; these enzymes are responsible for the β 1,2-GlcNAc linkage to the α 1,3-antenna and ablation of these genes results in a distinct change in the glycan pattern, which is, however, not accompanied by an apparent change of the phenotype under laboratory conditions,¹³ other than altered susceptibility to bacterial infection.³⁷ As expected, the complex and hybrid structures depending on the prior action of GnTI as well as the paucimannose glycans are absent in the triple knock out mutant; our own unpublished data also indicates a loss of PC-modified N-glycans. The methylated structures are missing, which is mainly due to the decrease of fucosylated structures; indeed, the N-glycans of this mutant carry maximally only two fucose residues. Glycans resulting from the action of GnTI-independent fucosyltransferase(s) acting on Hex₇₋₉GlcNAc₂ can be

The presence of anti-horseradish peroxidase epitopes in the triple GnTI knockout is one piece of evidence demonstrating that the worm's core α 1,3-fucosyltransferase (FUT-1) is rather unique. Whereas the overall 'result' of possessing core α 1,3-fucose (an epitope of anti-horseradish peroxidase) is the same in plants, insects, trematodes and nematodes, it is obvious that the specificity of FUT-1 is a result of convergent evolution as compared to the other species, since it is the only one described to date, which is GnTI-independent; furthermore, as mentioned above, the enzyme is prevented from acting when a GlcNAc residue is present on the α 1,3-antenna.⁶ This residue is, however, normally a prerequisite for the action of core fucosyltransferases. The *C. elegans* core α 1,6-fucosyltransferase, encoded by the *fut-8* gene, though, still requires the prior action of GnTI and is thus not differing from the other analysed invertebrate or vertebrate core fucosyltransferases.³⁸ Thus, to form difucosylated N-glycans in *C. elegans*, transfer by GnTI is followed by the consecutive actions of FUT-8, Golgi hexosaminidase and, finally, FUT-1.

Another key mutant, analysed in our laboratory, was the Golgi mannosidase II mutant, which was shown to




Figure 4. Pathways in *C. elegans* leading to fucosylated paucimannosidic structures. This summary is not intended to be exhaustive, but shows a number of reactions proven in vitro or postulated to exist in vivo (particularly, phosphorylcholinyltransferases can probably modify any non-reducing-terminal GlcNAc); pathways to core chitobiose modifications have not been elucidated to date. Names of genes relevant for certain biosynthetic steps are indicated in brackets. Glycan nomenclature is based upon that introduced by Schachter with selected structures also shown in graphical forms.

lack, as expected, the paucimannosidic truncated structures, but had a whole subset of structures not found in the wild-type.¹⁴ When analysing the N-glycans, evidence for products of the transfer by core α 1,6 fucosyltransferase to Man5Gn was found (reflecting that this enzyme utilises MGn and Man5Gn and not only GnGn), whereas it was also obvious that FUT-1 modifies Man5 and that the phosphorylcholinyltransferase(s) modified Man5Gn. In the *hex-2* mutant, lacking a potential Golgi hexosaminidase, structures containing non-reducing terminal GlcNAc were enriched as well as structures with galactose-modified core α 1,6-fucose.¹² Overall, based on the knowledge we gained from analysing mutants and the substrate specificity of the relevant glycosyltransferases as well as previous summaries of the glycosylation capabilities of the worm,^{14,37,38} we can postulate the pathways shown in Figure 4.

Although, as stated above the pathway to the paucimannosidic fucosylated structures differs from the other invertebrates, the outcome of paucimannosidic fucosylated structures is similar. So why did *C. elegans* and probably the other nematodes undergo the effort to develop that difference? The clue may be to consider the highly-fucosylated structures such as the core chitobiose modifications which are probably processed from the paucimannosidic fucosylated structures; during their biosynthesis, the high hexosaminidase activity, which results in an absence of ‘complex’ substrates, is perhaps being functionally bypassed via the ‘GlcNAc-independent’ core α 1,3-fucosyltransferase FUT-1. These multifucosylated structures presumably represent an important set of modifications and, in other nematodes, are probably serving a special aim such as supporting the parasitic life-style as in *Haemonchus contortus*. However, under laboratory conditions *C. elegans* mutants lacking highly-fucosylated structures are still seemingly quite happy, although those lacking more-or-less all fucose (the *bre-1/gmd-1* mutant) do have lower brood sizes.³⁹ On the other hand, agar plates with *Escherichia coli* are not reflecting the normal nematodal life conditions. Indeed, as nematodes have specialised in synthesising such a range of unusual fucosylated structures, in comparison to other higher organisms in which both fucose and sialic acid are involved in recognition, one may expect some biological function also in the non-parasitic species, which requires alternative ‘stresses’ (e.g., infection) to be shown to be significant.

5. Conclusion

Finally, to recapitulate the possible and partly proven N-glycan modifications in *C. elegans* (see also Fig. 5): the core of the N-glycans can indeed carry α 1,3 and α 1,6 core fucose which in turn can be modified by galactose residues. The complex glycans carrying up to




Figure 5. Putative modifications of the core and the antennae present in *C. elegans*. Based on studies by various groups, predominantly using mass spectrometry, many of these features are, to date, unique to the worm. The typical oligomannosidic structures are not shown. The symbols used are blue squares for GlcNAc, green circles for Man, yellow circles for Gal, open circles for undefined hexose residues and red triangles for Fuc residues (nomenclature of the Consortium for Functional Glycomics).

three antennae can be capped with PC, whereas either an H-type modification or linkage of both galactose and fucose directly to the trimannosyl core (potentially methylated) have been also proposed; on the other hand, probably neither Lewis x, fucosylated LacdiNAc, bisecting GlcNAc nor tetraantennary glycans are expressed in *C. elegans*. Many of the N-glycan modifications are unique to the worm, but the study of those shared with parasitic worms, such as PC, which was found in *Ascaris suum*,⁴⁰ *Trichinella spiralis*²⁹ and filarial nematodes⁴¹ or trifucosylated core shared with *Haemonchus contortus*,⁴² may yield interesting therapeutic avenues.

Acknowledgements

Our work on *C. elegans* has been funded by the Austrian Fonds zur Förderung der wissenschaftlichen Forschung (Grants P15475 and P18447 to I.B.H.W.) We also thank other members of the group, especially Denise Kerner, and our collaborators Günter Lochnit (Justus-Liebig-Universität Gießen) and Verena Jantsch (Universität Wien) for their participation in these projects.

References

- Haslam, S. M.; Dell, A. *Biochimie* **2003**, *85*, 25–32.
- Gerdt, S.; Dennis, R. D.; Borgonie, G.; Schnabel, R.; Geyer, R. *Eur. J. Biochem.* **1999**, *266*, 952–963.
- Griffitts, J. S.; Haslam, S. M.; Yang, T.; Garczynski, S. F.; Mulloy, B.; Morris, H.; Cremer, P. S.; Dell, A.; Adang, M. J.; Aroian, R. V. *Science* **2005**, *307*, 922–925.
- Guerardel, Y.; Balanzino, L.; Maes, E.; Leroy, Y.; Coddeville, B.; Oriol, R.; Strecker, G. *Biochem. J.* **2001**, *357*, 167–182.

5. Harnett, W.; Harnett, M. M. *Biochim. Biophys. Acta* **2001**, 1539, 7–15.
6. Paschinger, K.; Rendić, D.; Lochnit, G.; Jantsch, V.; Wilson, I. B. H. *J. Biol. Chem.* **2004**, 279, 49588–49598.
7. Natsuka, S.; Kawaguchi, M.; Wada, Y.; Ichikawa, A.; Ikura, K.; Hase, S. *J. Biochem. (Tokyo)* **2005**, 138, 209–213.
8. Cipollo, J. F.; Awad, A. M.; Costello, C. E.; Hirschberg, C. B. *J. Biol. Chem.* **2005**, 280, 26063–26072.
9. Haslam, S. M.; Gems, D.; Morris, H. R.; Dell, A. *Biochem. Soc. Symp.* **2002**, 69, 117–134.
10. Hanneman, A. J.; Rosa, J. C.; Ashline, D.; Reinhold, V. N. *Glycobiology* **2006**, 16, 874–890.
11. Hirabayashi, J.; Hayama, K.; Kaji, H.; Isobe, T.; Kasai, K. *J. Biochem. (Tokyo)* **2002**, 132, 103–114.
12. Gutternigg, M.; Kretschmer-Lubich, D.; Paschinger, K.; Rendić, D.; Hader, J.; Geier, P.; Ranftl, R.; Jantsch, V.; Lochnit, G.; Wilson, I. B. H. *J. Biol. Chem.* **2007**, 282, 27825–27840.
13. Zhu, S.; Hanneman, A.; Reinhold, V.; Spence, A.; Schachter, H. *Biochem. J.* **2004**, 382, 995–1001.
14. Paschinger, K.; Hackl, M.; Gutternigg, M.; Kretschmer-Lubich, D.; Stemmer, U.; Jantsch, V.; Lochnit, G.; Wilson, I. B. H. *J. Biol. Chem.* **2006**, 281, 28265–28277.
15. Natsuka, S.; Adachi, J.; Kawaguchi, M.; Nakakita, S.; Hase, S.; Ichikawa, A.; Ikura, K. *J. Biochem. (Tokyo)* **2002**, 131, 807–813.
16. Cipollo, J. F.; Costello, C. E.; Hirschberg, C. B. *J. Biol. Chem.* **2002**, 277, 49143–49157.
17. Cipollo, J. F.; Awad, A. M.; Costello, C. E.; Hirschberg, C. B. *J. Biol. Chem.* **2004**, 279, 52893–52903.
18. *Glycogenomics: The Impact of Genomics and Informatics in Glycobiology*; Drickamer, K., Dell, A., Eds.; Portland Press: London, 2002.
19. Haslam, S. M.; Coles, G. C.; Morris, H. R.; Dell, A. *Glycobiology* **2000**, 10, 223–229.
20. Haslam, S. M.; Coles, G. C.; Munn, E. A.; Smith, T. S.; Smith, H. F.; Morris, H. R.; Dell, A. *J. Biol. Chem.* **1996**, 271, 30561–30570.
21. Duffy, M. S.; Morris, H. R.; Dell, A.; Appleton, J. A.; Haslam, S. M. *Glycobiology* **2006**, 16, 854–862.
22. Zhang, Y.; Iwasa, T.; Tsuda, M.; Kobata, A.; Takasaki, S. *Glycobiology* **1997**, 7, 1153–1158.
23. Wuhler, M.; Robijn, M. L.; Koeleman, C. A.; Balog, C. I.; Geyer, R.; Deelder, A. M.; Hokke, C. H. *Biochem. J.* **2004**, 378, 625–632.
24. Kavar, Z.; van Die, I.; Cummings, R. D. *J. Biol. Chem.* **2002**, 277, 34924–34932.
25. Kavar, Z. S.; Haslam, S. M.; Morris, H. R.; Dell, A.; Cummings, R. D. *J. Biol. Chem.* **2005**, 280, 12810–12819.
26. Robijn, M. L.; Wuhler, M.; Kornelis, D.; Deelder, A. M.; Geyer, R.; Hokke, C. H. *Parasitology* **2005**, 130, 67–77.
27. Wuhler, M.; Koeleman, C. A.; Deelder, A. M.; Hokke, C. H. *FEBS J.* **2006**, 273, 347–361.
28. Wuhler, M.; Koeleman, C. A.; Fitzpatrick, J. M.; Hoffmann, K. F.; Deelder, A. M.; Hokke, C. H. *Glycobiology* **2006**, 16, 991–1006.
29. Morelle, W.; Haslam, S. M.; Olivier, V.; Appleton, J. A.; Morris, H. R.; Dell, A. *Glycobiology* **2000**, 10, 941–950.
30. Kubelka, V.; Altmann, F.; Staudacher, E.; Tretter, V.; März, L.; Hård, K.; Kamerling, J. P.; Vliegthart, J. F. G. *Eur. J. Biochem.* **1993**, 213, 1193–1204.
31. Altmann, F.; Schwihla, H.; Staudacher, E.; Glössl, J.; März, L. *J. Biol. Chem.* **1995**, 270, 17344–17349.
32. Nguyen, K.; Van Die, I.; Grundahl, K. M.; Kavar, Z. S.; Cummings, R. D. *Glycobiology* **2007**, 17, 586–599.
33. Khoo, K.-H.; Sarda, S.; Xu, X.; Caulfield, J. P.; McNeil, M. R.; Homans, S. W.; Morris, H. R.; Dell, A. *J. Biol. Chem.* **1995**, 270, 17114–17123.
34. Khoo, K. H.; Chatterjee, D.; Caulfield, J. P.; Morris, H. R.; Dell, A. *Glycobiology* **1997**, 7, 653–661.
35. Wuhler, M.; Kantelhardt, S. R.; Dennis, R. D.; Doenhoff, M. J.; Lochnit, G.; Geyer, R. *Eur. J. Biochem.* **2002**, 269, 481–493.
36. Altmann, F.; Fabini, G.; Ahorn, H.; Wilson, I. B. H. *Biochimie* **2001**, 83, 703–712.
37. Shi, H.; Tan, J.; Schachter, H. *Methods Enzymol.* **2006**, 417, 359–389.
38. Paschinger, K.; Staudacher, E.; Stemmer, U.; Fabini, G.; Wilson, I. B. H. *Glycobiology* **2005**, 15, 463–474.
39. Barrows, B. D.; Haslam, S. M.; Bischof, L. J.; Morris, H. R.; Dell, A.; Aroian, R. V. *J. Biol. Chem.* **2007**, 282, 3302–3311.
40. Pörtl, G.; Kerner, D.; Paschinger, K.; Wilson, I. B. H. *FEBS J.* **2007**, 274, 714–726.
41. Haslam, S. M.; Houston, K. M.; Harnett, W.; Reason, A. J.; Morris, H. R.; Dell, A. *J. Biol. Chem.* **1999**, 274, 20953–20960.
42. Haslam, S. M.; Coles, G. C.; Reason, A. J.; Morris, H. R.; Dell, A. *Mol. Biochem. Parasitol.* **1998**, 93, 143–147.